The cardiovascular phenotype of a mouse model of acromegaly

Growth Hormone and IGF Research

Volumn 19, Issue 5, 2009, Pages 413-419

  Izzard, Ashley S ^a   Emerson, Michael ^a   Prehar, Sukhpal ^a   Neyses, Ludwig ^a   Trainer, Peter ^a   List, Edward O ^b   Kopchick, John J ^b   Heagerty, Anthony M ^a  

^a Maternal and Fetal Health Research Centre   (United Kingdom)

^b OHIO UNIVERSITY   (United States)

Author keywords

Acromegaly; Blood pressure; Cardiac hypertrophy; Small arteries

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR;

ACROMEGALY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL; BODY MASS; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR SYSTEM; CIRCULATION; CORONARY ARTERY DISEASE; FEMALE; GENE OVEREXPRESSION; GIGANTISM; HEART HEMODYNAMICS; HEART HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; INSULIN RESISTANCE; LARON SYNDROME; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ACROMEGALY; ANIMALS; CARDIOVASCULAR SYSTEM; GROWTH HORMONE; MICE; MICE, TRANSGENIC; MYOCARDIAL CONTRACTION; ORGAN SIZE; PHENOTYPE;

EID: 70349348922     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.12.006     Document Type: Article

References (40)

1. Bollano E., Omerovic E., Bohlooly-y M., et al. Impairment of cardiac function and bioenergetics in adult transgenic mice overexpressing the bovine growth hormone gene. Endocrinology 141 6 (2000) 2229-2235
2. Irving R.J., Carson M.N., Webb D.J., and Walker B.R. Peripheral vascular structure and function in men with contrasting GH levels. J. Clin. Endocrinol. Metab. 87 7 (2002) 3309-3314
3. Maison P., Demolis P., Young J., Schaison G., Giudicelli J.F., and Chanson P. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clin. Endocrinol. (Oxf) 53 4 (2000) 445-451
4. Otsuki M., Kasayama S., Yamamoto H., et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients. Clin. Endocrinol. (Oxf) 54 6 (2001) 791-796
5. Thomas M.O., Vance M.L., Laws E.R., Horvath E., and Kovacs K. The anterior pituitary. In: Williams R.H., and Wilson J.D. (Eds). Williams Textbook of Endocrinology (1998), Saunders, Philadelphia 295-307
6. Lu C., Schwartzbauer G., Sperling M.A., et al. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J. Biol. Chem. 276 25 (2001) 22892-22900
7. Li Q., Wu S., Li S.Y., et al. Cardiac-specific overexpression of insulin-like growth factor 1 attenuates aging-associated cardiac diastolic contractile dysfunction and protein damage. Am. J. Physiol. Heart Circ. Physiol. 292 3 (2007) H1398-H1403
8. Connell J.M.C., and Davies D.L. Endocrine hypertension thyroid disease and acromegaly. In: Swales J.D. (Ed). Textbook of Hypertension (1994), Blackwell Science Publishing, Oxford 959-968
9. Lie J.T. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am. Heart J. 100 1 (1980) 41-52
10. Spinelli L., Petretta M., Verderame G., et al. Left ventricular diastolic function and cardiac performance during exercise in patients with acromegaly. J. Clin. Endocrinol. Metab. 88 9 (2003) 4105-4109
11. Colao A., Spiezia S., Cerbone G., et al. Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin. Endocrinol. (Oxf) 54 4 (2001) 515-524
12. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc. Res. 30 6 (1995) 825-834
13. Ito H., Hiroe M., Hirata Y., et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 87 5 (1993) 1715-1721
14. Colao A., Spinelli L., Cuocolo A., et al. Cardiovascular consequences of early-onset growth hormone excess. J. Clin. Endocrinol. Metab. 87 7 (2002) 3097-3104
15. Harrap S.B., Macpherson F., Wilson V.G., et al. Failure of chronic administration of growth hormone to affect blood pressure, vascular reactivity and sodium metabolism in normal rats. J. Hypertens. Suppl. 6 4 (1988) S170-S172
16. Bruel A., Oxlund H., and Nyengaard J.R. The total length of myocytes and capillaries, and total number of myocyte nuclei in the rat heart are time-dependently increased by growth hormone. Growth Horm. IGF Res. 15 4 (2005) 256-264
17. Kopchick J.J., Bellush L.L., and Coschigano K.T. Transgenic models of growth hormone action. Annu. Rev. Nutr. 19 (1999) 437-461
18. Chen N.Y., Chen W.Y., and Kopchick J.J. A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 137 11 (1996) 5163-5165
19. Chen W.Y., Wight D.C., Mehta B.V., Wagner T.E., and Kopchick J.J. Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol. Endocrinol. 5 12 (1991) 1845-1852
20. K.T. Coschigano, A.N. Holland, M.E. Riders, J.J. Kopchick, Altered growth hormone signalling in two lines of dwarf mice results in diet-induced obesity and hyperinsulinemia but not diabetes, in: 84th Annual Meeting of the Endocrine Society, 2002 (Abstract P3-303:561).
21. Coschigano K.T., Holland A.N., Riders M.E., List E.O., Flyvbjerg A., and Kopchick J.J. Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span. Endocrinology 144 9 (2003) 3799-3810
22. Knapp J.R., Chen W.Y., Turner N.D., Byers F.M., and Kopchick J.J. Growth patterns and body composition of transgenic mice expressing mutated bovine somatotropin genes. J. Anim. Sci. 72 11 (1994) 2812-2819
23. Quaife C.J., Mathews L.S., Pinkert C.A., Hammer R.E., Brinster R.L., and Palmiter R.D. Histopathology associated with elevated levels of growth hormone and insulin-like growth factor I in transgenic mice. Endocrinology 124 1 (1989) 40-48
24. Dilley R.J., and Schwartz S.M. Vascular remodeling in the growth hormone transgenic mouse. Circ. Res. 65 5 (1989) 1233-1240
25. Bohlooly Y., Carlson L., Olsson B., et al. Vascular function and blood pressure in GH transgenic mice. Endocrinology 142 8 (2001) 3317-3323
26. Egecioglu E., Andersson I.J., Bollano E., et al. Growth hormone receptor deficiency in mice results in reduced systolic blood pressure and plasma renin, increased aortic eNOS expression, and altered cardiovascular structure and function. Am. J. Physiol. Endocrinol. Metab. 292 5 (2007) E1418-E1425
27. Berryman D.E., List E.O., Coschigano K.T., Behar K., Kim J.K., and Kopchick J.J. Comparing adiposity profiles in three mouse models with altered GH signaling. Growth Horm. IGF Res. 14 4 (2004) 309-318
28. Zhou Y., Xu B.C., Maheshwari H.G., et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. USA 94 24 (1997) 13215-13220
29. Chandrashekar V., Bartke A., Coschigano K.T., and Kopchick J.J. Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology 140 3 (1999) 1082-1088
30. Izzard A.S., Bund S.J., and Heagerty A.M. Myogenic tone in mesenteric arteries from spontaneously hypertensive rats. Am. J. Physiol. 270 1 Pt 2 (1996) H1-H6
31. Osol G., and Halpern W. Myogenic properties of cerebral blood vessels from normotensive and hypertensive rats. Am. J. Physiol. 249 5 Pt 2 (1985) H914-H921
32. Rizzoni D., Porteri E., Giustina A., et al. Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries. Hypertension 43 3 (2004) 561-565
33. Izzard A.S., Rizzoni D., Gabiti-Rosei E., and Heagerty A.M. Small artery structure and hypertension: adaptive changes and target organ damage. J. Hypertens. 23 2 (2005) 247-250
34. Schofield I., Malik R., Izzard A., Austin C., and Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 106 24 (2002) 3037-3043
35. Doi T., Striker L.J., Quaife C., et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulin like growth factor-1. Am. J. Pathol. 131 3 (1988) 398-403
36. Izzard A.S., Graham D., Burnham M.P., Heerkens E.H., Dominiczak A.F., and Heagerty A.M. Myogenic and structural properties of cerebral arteries from the stroke-prone spontaneously hypertensive rat. Am. J. Physiol. Heart Circ. Physiol. 285 4 (2003) H1489-H1494
37. Colao A., Pivonello R., Auriemma R.S., et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154 3 (2006) 467-477
38. Pivonello R., Galderisi M., Auriemma R.S., et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J. Clin. Endocrinol. Metab. 92 2 (2007) 476-482
39. Kusano K., Tsutsumi Y., Dean J., et al. Long-term stable expression of human growth hormone by rAAV promotes myocardial protection post-myocardial infarction. J. Mol. Cell. Cardiol. 42 2 (2007) 390-399
40. Colligan P.B., Brown-Borg H.M., Duan J., Ren B.H., and Ren J. Cardiac contractile function is enhanced in isolated ventricular myocytes from growth hormone transgenic mice. J. Endocrinol. 173 2 (2002) 257-264